Clinical Trials

AstraZeneca announced positive interim results from the Phase III VOLGA clinical trial, showing that perioperative treatment with Imfinzi combined with neoadjuvant enfortumab vedotin…
Read More...

Madrigal Pharmaceuticals, Inc. has entered into an exclusive global licensing agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-PNPLA3, a clinical-stage…
Read More...

Akeso, Inc. has announced that its novel trispecific antibody candidate, AK150, has received Investigational New Drug (IND) clearance from the National Medical Products Administration…
Read More...

Vima Therapeutics has announced significant progress in the development of its experimental treatment for movement disorders, revealing that the first patient has been dosed in a Phase…
Read More...

Biotechnology companies Akeso, Inc. and INOVIO have announced a clinical trial collaboration and supply agreement to evaluate a new combination immunotherapy approach for glioblastoma…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and…
Read More...

IQVIA, a global provider of clinical research services, healthcare intelligence, and commercial insights, has entered into a strategic long-term collaboration with Boehringer Ingelheim…
Read More...

GSK plc has reported positive results from two pivotal phase III clinical trials evaluating bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B…
Read More...

Takeda Pharmaceutical Company has announced it will discontinue its cell therapy research and development efforts as part of a broader strategic portfolio prioritization. The company…
Read More...

Harmony Biosciences Holdings, Inc. has released topline results from its Phase 3 RECONNECT Study evaluating ZYN002, a transdermal cannabidiol gel, in patients with Fragile X syndrome…
Read More...

Cellectar Biosciences, a late-stage clinical biopharmaceutical company specializing in cancer drug development, has entered into an agreement with Evestia Clinical to provide full…
Read More...

The New England Journal of Medicine has published the results from Novo Nordisk’s OASIS 4 Phase 3 trial, marking a major advance in obesity treatment with the investigational once-daily…
Read More...

Altasciences and VoxCell BioInnovation have announced a strategic collaboration aimed at transforming preclinical drug development by integrating advanced 3D bioprinted tissue models…
Read More...

Advarra announced the launch of the Council for Responsible Use of AI in Clinical Trials. The Council, which includes leaders from across the life sciences industry, will focus on…
Read More...

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational drug DYNE-101 for the treatment of…
Read More...

Capsida Biotherapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class…
Read More...

Novo Nordisk announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance…
Read More...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured…
Read More...

The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically…
Read More...